POLYMORPHISMS OF HPC2/ELAC2 AND SRD5A2
(5α-Reductase Type II) GENES IN PROSTATE CANCER
İzmirli M1,*, Arikan B2, Bayazit Y3, Alptekin D4
*Corresponding Author: Muzeyyen İzmirli, Department of Medical Biology, Faculty of Medicine, Bezmialem
Vakif University, 34093, Istanbul, Turkey; Tel.: +90-212-523-37-19, Fax: +90-212-523-23-26;
E-mail: muzeyyenizmirli@gmail.com.
page: 31
|
|
REFERENCES
1. Simard J, Dumont M, Labuda, Sinnett D, Meloche C,
El-Alfy M, Berger L, Lees E, Labrie F, Tavtigian SV.
Prostate cancer susceptibility genes: lessons learned
and challenges posed. Endocr Relat Cancer. 2003;
10(2): 225-259.
2. Takaku H, Minagawa W, Takagi M, Nashimot M. The
N-terminal half-domain of the long form of tRNase Z is
required for the Rnase 65 activity. Nucleic Acids Res.
2004; 32(15): 4429-4438.
3. Kover W, Guevara C, Chen, Y. Neuteboom S, Bookstein
R, Tavtigian S, Lees E. The product of candidate prostate
cancer susceptibility gene ELAC2 interacts with the
γ-tubulin complex. Int. J Cancer. 2003; 104(3): 283-288.
4. Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg
S, Martin A, Nathanson KL, Wein AJ, Malkowicz B.
Association of HPC2/ELAC2 genotypes and prostate
cancer. Am J Hum Genet. 2000; 67(4): 1010-1019.
5. Thigpen AE, Cala KM, Russell DW. Characterization
of Chinese hamster ovary cell lines expressing human
steroid 5α-reductase isozymes. J Biol Chem. 1993; 268
(23): 17404-17412.
6. Reichardt JKV, Makridakis N, Henderson BE, Yu MC,
Pike MC, Ross RK. Genetic variability of the human
SRD5A2 gene: implications for prostate cancer risk.
Cancer Res. 1995; 55(18): 3973-3975.
7. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk
FZ, Kolonel LN, Shi CY, Yu MC, Henderson BE,
Reichardt JKV. A prevalent missense substitution that
modulates activity of prostatic steroid 5α-reductase.
Cancer Res. 1997; 57(6): 1020-1022.
8. Labrie F, Sagimoto Y, Luu-The V, Simard J, Lachance
Y, Bachvarov D, Leblanc G, Durocher F, Paquet N.
Structure of human type II 5α-reductase gene. Endocrinology.
1992; 131(3): 1571-1573.
9. Jaffe JM, Malkowicz B, Walker AH, MacBride S, Peschel
R, Tomaszewski J, Arsdalen KV, Wein AJ, Rebbeck
TR. Association of SRD5A2 genotype and pathological
characteristics of prostate tumors. Cancer Res.
2000; 60(6): 1626-1630.
10. Miller SA, Dykes DD, Polesky HF. A simple salting out
procedure for extracting DNA from human nucleated
cells. Nucleic Acids Res. 1988; 16(3): 1215.
11. Cicek MS, Conti DV, Curran A, Neville PJ, Paris PL,
Casey G, Witte JS. Association of prostate cancer risk and
aggressiveness to androgen pathway genes: SRD5A2,
CYP17, and the AR. Prostate. 2004; 59(1): 69-76.
12. Stanford JL, Sabacan LP, Noonan EA, Iwasaki L, Shu
J, Feng Z, Ostrander EA. Association of HPC2/ ELAC2
polymorphisms with risk of prostate cancer in a population-
based study. Cancer Epidemiol Biomarkers Prev.
2003; 12(9): 876-881.
13. Camp NJ, Swensen J, Horne BD, Farnham JM, Thomas
A, Cannon-Albright LA, Tavtigian SV. Characterization
of linkage disequilibrium structure, mutation history,
and tagging SNPs, and their use in association analyses:
ELAC2 and famlial early-onset prostate cancer. Genet
Epidemiol. 2005; 28(3): 232-243.
14. Meitz JC, Edwards SM, Easton DF, Murkin A, Ardern-
Jones A, Jackson RA, Williams S, Dearnaley DP, Stratton
MR, Houlston RS. HPC2/ELAC2 polymorphisms
and prostate cancer risk: analysis age of onset of disease.
Br J Cancer. 2002; 87(8): 905-908.
15. Adler D, Kanji N, Trpkoy K, Fick G, Hughes RM.
HPC2/ELAC2 gene variants associated with incident
prostate cancer. J Hum Genet. 2003; 48(12): 634-638.
16. Rökman A, Ikonen T, Mononen N, Autio V, Matikainen
MP, Koivisto PA, Tammela TLJ, Kallioniemi OP,
Schleutker J. ELAC2/HPC2 involvement in hereditary
and sporadic prostate cancer. Cancer Res. 2001; 61(16):
6038-6041.
17. Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen
E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen
SJ, Cerhan JR, Blute ML, Schald DJ, Thibodeau
SN. Role of HPC2/ELAC2 in hereditary prostate cancer.
Cancer Res. 2001; 61(17): 6494-6499.
18. Vesprini D, Nam RK, Trachtenberg J, Jewett MAS, Tavtigian
SV, Emami M, Ho M, Toi A, Narod SA. HPC2
variants and screen-detected prostate cancer. Am J Hum
Genet. 2001; 68(4): 912-917.
19. Yokomizo A, Koga H, Kinukawa N, Tsukamoto T, Hirao
Y, Akaza H, Mori M, Naito S. HPC2/ELAC2 polymorphism
associated with Japanese sporadic prostate
cancer. Prostate. 2004; 61(3): 248-252.
20. Makridakis NM, Reichardt JK. Molecular epidemiology
of hormone-metabolic loci in prostate cancer. Epidemiol
Rev. 2001; 23(1): 24-29.
21. Latil AG, Azzouzi R, Cancel GS, Gulllaume EC, Cochan-
Priollet C, Berthon PL, Cussenot O. Prostate carcinoma
risk and allelic variants of genes involved in androgen
biosynthesis and metabolism pathways. Cancer.
2001; 92(5): 1130-1137.
22. Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman
DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA,
Mostofi FK, Stanczyk FZ, Reichardt JKV. Polymorphic
markers in the SRD5A2 gene and prostate cancer risk: a
population-based case-control study. Cancer Epidemiol
Biomarkers Prev. 2001; 10(10): 1077-1082.
23. Onen IH, Ekmekci A, Eroglu M, Polat F, Biri H. The
association of 5α-reductase type II (SRD5A2) and 17
hydroxylase (CYP17) gene polymorphisms with prostate
cancer patients in the Turkish population. DNA
Cell Biol. 2007; 26(2): 100-107.
24. Nam RK, Toi A, Vesprini D, Ho M, Sweet J, Trachtenberg
J, Jewett MAS, Narod SA. V89L polymorphism
of type-2, 5α-reductase enzyme gene predicts prostate
cancer presence and progression. Urology. 2001; 57
(1): 199-204.
25. Neslund-Dudas C, Bock CH, Monaghan K, Nock NL,
Yang JJ, Rundle A, Tang D, Rybicki BA. SRD5A2 and
HSD3B2 polymorphisms are associated with prostate
cancer risk and aggressiveness. Prostate. 2007; 67(15):
1654-1663.
26. Li Z, Habuchi T, Mitsumori K, Kamoto T, Kinoshitu
H, Segawa T, Ogava O, Kato T. Association of V89L
SRD5A2 polymorphism with prostate cancer development
in a Japanese population. J Urol. 2003; 169(6):
2378-2381.
27. Rajender S, Vuayalakshmi K, Pooja S, Madhavi S, Paul
SFD, Vettriselvi V, Shroff S, Singh L, Thangaraj K.
Longer (TA)n repeat but not A49T and V89L polymorphisms
in SRD5A2 gene may confer prostate cancer
risk in South Indian men. J Androl. 2009; 30(6): 703-
710.
28. Soderstrom TG, Bjelfman C, Brekkan E, Ask B, Egevad
L, Norlen BJ, Rane A. Messenger ribonucleic acid levels
of steroid 5α-reductase 2 in human prostate predict
the enzyme activity. J Clin Endocrinol Metab. 2001;
86(2): 855-858.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
